pharma · Melanoma · Multiple Myeloma · RNA
Atrium Therapeutics
Atrium Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker RNA. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Germ Cell Tumor, Renal Carcinoma, Acut
10578 Science Center Dr, Suite 125, San Diego, California 92121, US HQ
2026 Founded
46 Employees
Public company Type
RNA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10578 Science Center Dr, Suite 125, San Diego, California 92121, US
- Founded
- 2026
- Employees
- 46
- Programs
- 31
- Drugs
- 33
- Patents
- 37
Olutasidenib
Phase 2 · small molecule · IDH1 Mutation
Olutasidenib for IDH1 Mutation is a Phase 2 program (small_molecule) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code HCRN-AML24-687
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Atrium Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- IDH1 Mutation
- Status
- active
- Trials
- 1